Works by Lee, Kyung-Hun

Results: 121
    1

    Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy.

    Published in:
    JNCI Cancer Spectrum, 2020, v. 4, n. 1, p. N.PAG, doi. 10.1093/jncics/pkz085
    By:
    • Rugo, Hope S;
    • Ettl, Johannes;
    • Hurvitz, Sara A;
    • Gonçalves, Anthony;
    • Lee, Kyung-Hun;
    • Fehrenbacher, Louis;
    • Mina, Lida A;
    • Diab, Sami;
    • Woodward, Natasha E;
    • Yerushalmi, Rinat;
    • Goodwin, Annabel;
    • Blum, Joanne L;
    • Martin, Miguel;
    • Quek, Ruben G W;
    • Tudor, Iulia Cristina;
    • Bhattacharyya, Helen;
    • Gauthier, Eric;
    • Litton, Jennifer K;
    • Eiermann, Wolfgang
    Publication type:
    Article
    2
    3

    Establishment and characterization of 24 breast cancer cell lines and 3 breast cancer organoids reveals molecular heterogeneity and drug response variability in malignant pleural effusion-derived models.

    Published in:
    Breast Cancer Research, 2025, v. 27, n. 1, p. 1, doi. 10.1186/s13058-025-02032-7
    By:
    • Kim, Soon-Chan;
    • Kim, Ga-Hye;
    • Park, Jae-Hyeon;
    • Lee, Kyung-Hun;
    • Koh, Jiwon;
    • Kim, Tae-Yong;
    • Lee, Dae-Won;
    • Kim, Yu-Jin;
    • Kim, Seongyeong;
    • Park, Song-Yi;
    • Min, Ahrum;
    • Shin, Young-Kyoung;
    • Im, Seock-Ah;
    • Ku, Ja-Lok
    Publication type:
    Article
    4
    5
    6

    Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy.

    Published in:
    Journal of Cancer Research & Clinical Oncology, 2016, v. 142, n. 3, p. 707, doi. 10.1007/s00432-015-2072-5
    By:
    • Kim, Hyori;
    • Youk, Jeonghwan;
    • Yang, Yaewon;
    • Kim, Tae-Yong;
    • Min, Ahrum;
    • Ham, Hye-Seon;
    • Cho, Seongcheol;
    • Lee, Kyung-Hun;
    • Keam, Bhumsuk;
    • Han, Sae-Won;
    • Oh, Do-Youn;
    • Ryu, Han;
    • Han, Wonshik;
    • Park, In;
    • Kim, Tae-You;
    • Noh, Dong-Young;
    • Im, Seock-Ah
    Publication type:
    Article
    7
    8
    9
    10
    11
    12
    13

    Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer.

    Published in:
    Cancer Immunology, Immunotherapy, 2024, v. 73, n. 10, p. 1, doi. 10.1007/s00262-024-03782-7
    By:
    • Park, Changhee;
    • Suh, Koung Jin;
    • Kim, Se Hyun;
    • Lee, Kyung-Hun;
    • Im, Seock-Ah;
    • Kim, Min Hwan;
    • Sohn, Joohyuk;
    • Jeong, Jae Ho;
    • Jung, Kyung Hae;
    • Lee, Kyoung Eun;
    • Park, Yeon Hee;
    • Kim, Hee-Jun;
    • Cho, Eun Kyung;
    • Choi, In Sil;
    • Noh, Seung-Jae;
    • Shin, Inkyung;
    • Cho, Dae-Yeon;
    • Kim, Jee Hyun
    Publication type:
    Article
    14
    15

    Predictive biomarkers for 5-fluorouracil and oxaliplatin-based chemotherapy in gastric cancers via profiling of patient-derived xenografts.

    Published in:
    Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-25122-4
    By:
    • Na, Deukchae;
    • Chae, Jeesoo;
    • Cho, Sung-Yup;
    • Kang, Wonyoung;
    • Lee, Ahra;
    • Min, Seoyeon;
    • Kang, Jinjoo;
    • Kim, Min Jung;
    • Choi, Jaeyong;
    • Lee, Woochan;
    • Shin, Dongjin;
    • Min, Ahrum;
    • Kim, Yu-Jin;
    • Lee, Kyung-Hun;
    • Kim, Tae-Yong;
    • Suh, Yun-Suhk;
    • Kong, Seong-Ho;
    • Lee, Hyuk-Joon;
    • Kim, Woo-Ho;
    • Park, Hansoo
    Publication type:
    Article
    16
    17
    18
    19
    20
    21
    22
    23

    Response to Sung, Rosenberg, and Yang.

    Published in:
    2020
    By:
    • Lin, Ching-hung;
    • Yap, Yoon sim;
    • Lee, Kyung-hun;
    • Yeo, Winnie;
    • Ueno, Takayuki;
    • Li, Huiping;
    • Huang, Shu-min;
    • Lu, Yen-shen
    Publication type:
    Letter
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37

    HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2013, v. 72, n. 1, p. 109, doi. 10.1007/s00280-013-2174-1
    By:
    • Kim, Ji-Won;
    • Kim, Jee;
    • Im, Seock-Ah;
    • Kim, Yu;
    • Han, Hye-Suk;
    • Kim, Jin-Soo;
    • Lee, Kyung-Hun;
    • Kim, Tae-Yong;
    • Han, Sae-Won;
    • Jeon, Yoon;
    • Oh, Do-Youn;
    • Kim, Tae-You;
    • Park, In
    Publication type:
    Article
    38
    39

    Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 4, p. 843, doi. 10.1007/s00280-013-2075-3
    By:
    • Lee, Kyung-Hun;
    • Chang, Hye;
    • Han, Sae-Won;
    • Oh, Do-Youn;
    • Im, Seock-Ah;
    • Bang, Yung-Jue;
    • Kim, Sun;
    • Lee, Keun-Wook;
    • Kim, Jee;
    • Hong, Yong;
    • Kim, Tae;
    • Park, Young;
    • Kang, Won;
    • Shin, Sang;
    • Ahn, Joong;
    • Kang, Gyeong;
    • Jeong, Seung-Yong;
    • Park, Kyu;
    • Park, Jae-Gahb;
    • Kim, Tae-You
    Publication type:
    Article
    40
    41

    A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer.

    Published in:
    NPJ Breast Cancer, 2024, v. 10, n. 1, p. 1, doi. 10.1038/s41523-024-00684-w
    By:
    • Noguchi, Emi;
    • Yamanaka, Takashi;
    • Mukai, Hirofumi;
    • Yamamoto, Naohito;
    • Chung, Chi-Feng;
    • Lu, Yen-Shen;
    • Chang, Dwan-Ying;
    • Sohn, Joohyuk;
    • Kim, Gun Min;
    • Lee, Kyung-Hun;
    • Lee, Soo-Chin;
    • Iwasa, Tsutomu;
    • Iwata, Hiroji;
    • Watanabe, Kenichi;
    • Jung, Kyung Hae;
    • Tanabe, Yuko;
    • Kang, Seok Yun;
    • Yasojima, Hiroyuki;
    • Aogi, Kenjiro;
    • Tokunaga, Eriko
    Publication type:
    Article
    42
    43
    44

    A phase II trial of the pan‐HER inhibitor poziotinib, in patients with HER2‐positive metastatic breast cancer who had received at least two prior HER2‐directed regimens: results of the NOV120101‐203 trial.

    Published in:
    International Journal of Cancer, 2018, v. 143, n. 12, p. 3240, doi. 10.1002/ijc.31651
    By:
    • Park, Yeon Hee;
    • Lee, Kyung‐Hun;
    • Sohn, Joo Hyuk;
    • Lee, Keun Seok;
    • Jung, Kyung Hae;
    • Kim, Jee‐Hyun;
    • Lee, Ki Hyeong;
    • Ahn, Jin Seok;
    • Kim, Tae‐Yong;
    • Kim, Gun Min;
    • Park, In Hae;
    • Kim, Sung‐Bae;
    • Kim, Se Hyun;
    • Han, Hye Sook;
    • Im, Young‐Hyuck;
    • Ahn, Jin‐Hee;
    • Kim, Jung‐Yong;
    • Kang, Jahoon;
    • Im, Seock‐Ah
    Publication type:
    Article
    45
    46
    47
    48

    A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.

    Published in:
    Journal of Experimental & Clinical Cancer Research (17569966), 2022, v. 41, n. 1, p. 1, doi. 10.1186/s13046-022-02383-5
    By:
    • Chan, Stephen L.;
    • Schuler, Martin;
    • Kang, Yoon-Koo;
    • Yen, Chia-Jui;
    • Edeline, Julien;
    • Choo, Su Pin;
    • Lin, Chia-Chi;
    • Okusaka, Takuji;
    • Weiss, Karl-Heinz;
    • Macarulla, Teresa;
    • Cattan, Stéphane;
    • Blanc, Jean-Frederic;
    • Lee, Kyung-Hun;
    • Maur, Michela;
    • Pant, Shubham;
    • Kudo, Masatoshi;
    • Assenat, Eric;
    • Zhu, Andrew X.;
    • Yau, Thomas;
    • Lim, Ho Yeong
    Publication type:
    Article
    49
    50